Evommune (EVMN) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Evommune is the larger company by market cap ($224.3 million vs $223.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVMN | PRQR |
|---|---|---|
| Share price | $6.18 | $1.59 |
| Market cap | $224.29M | $223.67M |
| 1-day change | -0.64% | -2.76% |
| YTD return | -63.67% | -19.31% |
| 1-year return | — | -28.19% |
| 5-year return | — | -79.31% |
| EPS (TTM) | $-3.75 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.20 | $3.10 |
| 52-week low | $6.06 | $1.33 |
| Distance from 52-week high | -81.39% | -48.87% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +290.45% | +390.85% |
| Average volume | 697.98K | 808.31K |
| Shares outstanding | 36.29M | 141.12M |
| Employees | 48 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Evommune
EVMN stock →Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
EVMN vs PRQR FAQ
Which is bigger, Evommune or ProQR Therapeutics N.V.?
Evommune (EVMN) is larger, with a market capitalization of $224.29M compared with $223.67M for ProQR Therapeutics N.V. (PRQR).
Are Evommune and ProQR Therapeutics N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.